PEOPLE INTERVIEWED

His research over the past 25 years has focused on understanding the basic processes that control T cell activation and immune tolerance in autoimmunity and organ transplantation. He and members of his lab have developed soluble receptor antagonists, monoclonal antibodies and animals deficient in individual members of TCR and co-stimulatory pathways to define their individual roles in transplant rejection and autoimmunity including a special emphasis “regulatory T cells” (Treg). During the last several years, his research has adapted the animal studies using biologics and cell based therapies to develop therapeutics that can be used in humans with autoimmunity and under conditions of allotransplant rejection.

His laboratory performs independent research in tumor immunology and provides cutting-edge immune monitoring services for a wide variety of biomedical disciplines (cancer, infectious disease, rheumatology). His lab uses high parameter cytometry technologies, including 30-parameter flow cytometry and combined protein/mRNA analysis by RNA sequencing (molecular cytometry), to reveal biomarkers that predict patient outcomes, better understand disease pathogenesis, and inform rational design of combination drug therapies. Dr. Chattopadhyay serves as an Associate Editor for Cytometry, and was Scientific Chair for CYTO2019.

He has commercialized many life science products into new and emerging markets based on nascent technologies and advanced several drug screening programs from target identification to preclinical testing.

His specialties include cross-functional team leadership, marketing automation, NPS, project management, strategic planning, order to cash processes, channel management, product development, and plan execution. He is currently the strategic marketing lead for clinical flow cytometry.

George Karlin-Neumann joined QuantaLife in 2010. He has since transitioned to his current role as Director of Scientific Affairs at the Digital Biology Center at Bio-Rad Laboratories, where he is responsible for establishing and overseeing research collaborations exploring new directions for digital PCR technology.

He has received the Scholar Award from Ministry of Education and Culture of Japan, the Ito Foundation Award, the Nickel- V Foundation Award, and the STOP CANCER Award. At Roswell Park, along with his translational lab research, Dr. Koya leads an NIH funded prospective clinical trial based on an immune-modulator-enhanced TCR-engineered T cell transfer for metastatic cancer patients. He also serves as reviewer for scientific journals in the field of cancer research and immunology and as current reviewer for grants in NIH/NCI study sections.

He is the founding Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital.

The Kuchroo laboratory was the first to describe the TIM family of genes, and identified Tim-3 as an inhibitory receptor expressed on T cells, which are now being exploited for cancer immunotherapy. Dr. Kuchroo has 25 patents and has founded 5 different biotech companies including CoStim Pharmaceuticals and Tempero Pharmaceuticals. He also serves on the scientific advisory boards and works in an advisory capacity to a number of pharmaceutical companies including Biocon, Syngene, Pfizer, Novartis and GlaxoSmithKline (GSK).

Her laboratory develops novel targeted cancer treatment strategies. Dr. Munster’s basic research also involves studies on heritable factors of tumor development and treatment. Her clinical mission is to more rapidly translate novel scientific discovery to patient care with a goal to allow patients with incurable cancer real time and broader access to scientific advances. Dr. Munster has published in numerous scientific journals and textbooks, and recently authored Twisting Fate, about her experience as an oncologist and cancer patient.

Dr. Prins currently serves as director for the I3T Seminar Series, the Brain Tumor Immunology Research Lab and for many clinical trials of immunotherapy. His research centers on immune-based therapies for the treatment of central nervous system (CNS) tumors. Currently, patients presenting with such malignancies are left with few treatment options. His research group is attempting to apply what we learn from preclinical models toward the implementation of immunotherapy clinical trials for brain tumor patients.

By developing powerful protein-measuring tools, Dr. Paulovich helps to fill in this picture and open the door to treatments tailored to individual cancer patients.

Her team has spearheaded the development of assays that use a technique called multiple reaction monitoring mass spectrometry, or MRM-MS, to detect and precisely measure the amount of a particular protein. This technology will help researchers combine detailed information about proteins with genetic data to learn, for instance, which genetic mutations drive a cancer’s development and suggest new therapeutic targets.

Before joining the company in 1994, he started his scientific career at the Institute of Genetics, University of Cologne, where he wrote both his diploma thesis and his PhD thesis under the supervision of Prof. Dr. Andreas Radbruch. J.S. acquired a broad expertise in immunology including cellular and humoral immunology, which he constantly expanded. Today, he supervises a highly interdisciplinary team of about 260 employees, covering an entire spectrum of activities from basic research to applied research to product development. Tools for cell therapy and regenerative medicine have always been at the forefront of his activities at Miltenyi Biotec. J.S. is member of the American Society of Hematology (ASH), the American Association of Immunologists (AAI), the American Association for Cancer Research (AACR) and American Society of Gene & Cell Therapy (ASGCT).

He followed with a postdoctoral fellowship at the University of Chicago with Dr. Albert Bendelac where he worked to define the earliest molecular and epigenetic signals of Natural Killer T cell lineage commitment. Mike published fifteen peer reviewed manuscripts in the fields of airway biology, immunity to viral gene therapies, and developmental immunology. In addition to his scientific training, Mike holds a Master’s of Business Administration from the Questrom School of Business at Boston University. Since joining Taconic, Mike held positions in scientific marketing and product management, focused on aspects of competitive intelligence, business analytics, market forecasting and new product launch. He is currently the Vice President, Commercial Product Strategy, responsible for all commercial products.

Prior to joining the company, Quong served as the Director of Strategic Scientific Initiatives and Partnerships at the Frederick National Laboratory for Cancer Research, a federally funded research and development center sponsored by the National Cancer Institute.

Quong also served as a faculty member in the Department of Cancer Biology at Thomas Jefferson University and the Department of Oncology at Georgetown University. His research focused on systems biology approaches to understanding mechanisms of breast cancer resistance and biomarkers of therapeutic response. He has published extensively and served on the editorial boards of Cancer Research and The American Journal of Pathology. Prior to his time in academia, Quong was on staff at Lawrence Livermore National Laboratory and Sandia National Laboratories.

Quong completed his postdoctoral research at the Naval Research Laboratory as a National Research Council Fellow. He received his doctorate in physics from the University of California, Irvine, and undergraduate degrees in physics and applied mathematics from the University of California, Berkeley.

As General Manager, she has a broad portfolio of operational, regulatory and commercial responsibilities, supported by a broad knowledge of the entire preclinical development process gained from over 25 years’ working in drug discovery within Pharma, Biotech and Life Sciences organizations. Amanda Woodrooffe earned her PhD in in vitro drug-interactions from the University of Cambridge.